ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing [0.03%]
学术界ATMP开发和预GMP环境：早期细胞和基因治疗开发及生产的安全网
D N Silva,M Chrobok,G Ahlén et al.
D N Silva et al.
Advanced therapy medicinal products (ATMP) are medicines for human use that are based on genes, cells or tissues. Over the past years, an increasing number of ATMP entered the market for treatment of cancer, genetic disorders, skeletal defe...
Cell Squeeze: driving more effective CD8 T-cell activation through cytosolic antigen delivery [0.03%]
细胞挤压：通过胞质抗原递送更有效地激活CD8T细胞
J C Park,H Bernstein,S Loughhead et al.
J C Park et al.
Cell Squeeze is a novel technology that relies on temporarily disrupting the cell membrane to deliver cargo directly into the cytosol. This approach is applicable to a broad range of cell types (peripheral blood mononuclear cells, red blood...
Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments [0.03%]
来自非小细胞肺癌转移病灶的肿瘤浸润淋巴细胞产物的有效制备与其位置和既往治疗无关
S M Castenmiller,R de Groot,A Guislain et al.
S M Castenmiller et al.
Background: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Because current treatment regimens show limited success rates, alternative therapeutic approaches are needed. We r...
MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial [0.03%]
针对转移性黑色素瘤的外周血T细胞经 MART-1 TCR基因修饰治疗I/Iia期临床试验
M W Rohaan,R Gomez-Eerland,J H van den Berg et al.
M W Rohaan et al.
Background: Adoptive cell therapy with peripheral blood T cells expressing transgenic T-cell receptors (TCRs) is an innovative therapeutic approach for solid malignancies. We investigated the safety and feasibility of ado...
Microbiome-based interventions: therapeutic strategies in cancer immunotherapy [0.03%]
基于微生物组的干预措施：癌症免疫治疗中的治疗策略
C Soto Chervin,T F Gajewski
C Soto Chervin
The composition of the commensal microbiota has recently emerged as a key element influencing the efficacy of cancer treatments. It has become apparent that the interplay between the microbiome and immune system within the host influences t...
Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors [0.03%]
原型CD28ζ和4－1BBζ嵌合抗原受体的功能与进化研究
J Feucht,M Sadelain
J Feucht
T cells engineered to express chimeric antigen receptors (CARs) specific for CD19 have yielded remarkable clinical outcomes in patients with refractory B-cell malignancies. The first CARs to be approved by the US Food and Drug Administratio...
Immune checkpoints in thymic epithelial tumors: challenges and opportunities [0.03%]
胸腺上皮肿瘤中的免疫检查点：挑战和机遇
Nicolas Girard
Nicolas Girard
Thymic malignancies are rare mediastinal cancers, classified according to the World Health Organization's histopathologic classification which distinguishes thymomas from thymic carcinomas. One key consideration when discussing immunotherap...
John B Haanen
John B Haanen
Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer [0.03%]
肿瘤浸润淋巴细胞的过继性细胞疗法：非小细胞肺癌中下一代产品中克隆新抗原靶点的重要性日益增加
Jane Robertson,Max Salm,Markus Dangl
Jane Robertson
Immune checkpoint blockade has significantly improved clinical outcomes for patients with non-small cell lung cancer (NSCLC) and other solid tumours, but many patients do not respond and acquired resistance is common. Aspects of the tumour ...
Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors [0.03%]
瘤内免疫治疗：激活核酸感应型模式识别受体
Sudhir Agrawal,Ekambar R Kandimalla
Sudhir Agrawal
Recently, it has become clear that the tumour microenvironment (TME) is important in cancer immunotherapy. While immune checkpoint inhibitors are effective for some patients, the heterogeneous nature and status of the TME ('cold' tumours) p...